Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Золотой стандарт диагностики и лечения рака молочной железы 2022

Список литературы

  1. DeVita Jr, Rosenberg S.A., Lawrence T.S. Cancer: Principles & Practice of Oncology. Tenth Edition // L.W.W. P.
  2. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019.
  3. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2018 году. Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019.
  4. Members of the Breast Cancer Disease Site Group. Baseline staging tests in primarybreast cancer. Cancer Care Ontario, 2011.
  5. Tevaarwerk A.J., Wisinski K.B., O’Regan R.M. Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer // J. Oncol. Pract. 2016. Vol. 12, № 11. P. 1148–1156. 6. Obrzut M. et al. Does fine-needle aspiration biopsy still have a place in the diagnosis of breast lesions? // Przeglad Menopauzalny Menopause Rev. 2018. Vol. 17, № 1. P. 28–31.
  6. Кудайбергенова А. Перевод рекомендаций CAP. Протокол исследования инвазивного рака молочной железы. Общероссийская общественная организация «Российское общество онкомаммологов», 2016.
  7. Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol. 2010 May;23 Suppl 2:S52-9. doi: 1038/modpathol.2010.55. PMID: 20436503.
  8. Франк Георгий Авраамович. Рак молочной железы. Практическое руководство для врачей / Под ред. Г.А. Франка, Л.Э. Завалишиной и К.М. Пожарисского / РМАПО. – М., 2014. – 197
  9. St.Gallen-2015 in Vienna: News from a successful breast cancer conference transpositionю Senn HJ, Thürlimann B, Gnant M.Breast. 2015 Nov;24 Suppl 2:S1. doi: 10.1016/j.breast.2015.07.030. Epub 2015 Oct 4.
  10. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014 Feb;138(2):241-56. 12. Zhang Y., Ren H. Meta-analysis of diagnostic accuracy of magnetic resonance imaging and mammography for breast cancer // J. Cancer Res. Ther. 2017. Vol. 13, № 5. P. 862–868.
  11. Houssami N., Turner R.M., Morrow M. Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer // Breast Cancer Res. Treat. 2017. Vol. 165, № 2. P. 273–283.
  12. Rusch P. et al. Distant metastasis detected by routine staging in breast cancer patients participating in the national German screening programme: consequences for clinical practice // SpringerPlus. 2016. Vol. 5, № 1. P. 1010.
  13. Margolese R.G. et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial // Lancet Lond. Engl. 2016. Vol. 387, № 10021. P. 849–856.
  14. Hong S., Li J., Wang S. 18FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis // Surg. Oncol. 2013. Vol. 22, № 2. P. 139–143.
  15. Cook G.J.R., Azad G.K., Goh V. Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment // J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2016. Vol. 57. Suppl 1. P. 27S-33S.
  16. Cagney D.N. et al. Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer // JAMA Oncol. 2018. Vol. 4, № 7. P. 1001–1003.
  17. Cancer. Net Editorial Board. EKG and Echocardiogram // Navigating Cancer Care. American Society of Clinical Oncology.
  18. Любченко Л.Н. и др. Наследственный рак молочной железы: генетическая и клиническая гетерогенность, молекулярная диагностика, хирургическая профилактика в группах риска // Успехи молекулярной онкологии. № 2. P. 16–25.
  19. Cardoso F. et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2018. Vol. 29, № 8. P. 1634–1657.
  20. McCormick B., Winter K., Hudis C. et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy and observation. J. Clin. Oncol. 2015. Mar 20;33 (7):709–715.
  21. Marinovich M.L. et al. The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis // Ann. Surg. Oncol. 2016. Vol. 23, № 12. P. 3811–3821.
  22. Siponen E. et al. Surgical treatment in Paget’s disease of the breast // Am. J. Surg. 2010. Vol. 200, № 2. P. 241–246.
  23. Семиглазов В.Ф., Палтуев Р.М. Клинические рекомендации РООМ по диагностике и лечению рака молочной железы. 2018.
  24. Зикиряходжаев А.Д. и др. Состояние краев резекции при органосохраняющих операциях по поводу рака молочной железы // Онкология. Журнал им. П.А. Герцена. 2015. Т. 4, № 6. С. 65–73.
  25. England D.W. et al. Assessment of excision margins following wide local excision for breast carcinoma using specimen scrape cytology and tumour bed biopsy // Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 1994. Vol. 20, № 4. P. 425–429.
  26. Umpleby H.C. et al. Wide excision of primary breast cancer: the incidence of residual carcinoma at the site of excision // Ann. R. Coll. Surg. Engl. 1988. Vol. 70, № 4. P. 246–248.
  27. Thill M. MarginProbe: intraoperative margin assessment during breast conserving surgery by using radiofrequency spectroscopy // Expert Rev. Med. Devices. 2013. Vol. 10, № 3. P. 301–315.
  28. Mok C.W. Network meta-analysis of novel and conventional sentinel lymph node biopsy techniques in breast cancer // BJS Open. 2019.
  29. Ермощенкова М.В., Зикиряходжаев А.Д., Широких И.М., Тукмаков А.Ю., Масри А.А., Зипиров Г.М. Хирургическая реабилитация больных раком молочной железы на различных этапах комбинированного и комплексного лечения // Онкология. Журнал им. П.А. Герцена, 2019. Т. 8, № 3. С. 161–168.
  30. Lyman G.H. et al. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017. Vol. 35, № 5. P. 561–564.
  31. Giuliano A.E. et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial // JAMA. 2017. Vol. 318, № 10. P. 918–926.
  32. Портной С.М., Кузнецов А.В., Шакирова Н.М. Биопсия сигнального лимфатического узла с использованием флуоресцентной лимфографии у больных раком молочной железы cT1-4N0M0: высокие диагностические возможности // Вопросы онкологии. 2019. № 2. P. 243–249.
  33. Криворотько П.В. Клинические рекомендации РООМ по диагностике и лечению рака молочной железы. 2018.
  34. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breastconserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol. 2014;32:1507-15.
  35. Caudle A.S. et al. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2016. Vol. 34, № 10. P. 1072–1078.
  36. Cabıoğlu N. et al. Improved False-Negative Rates with Intraoperative Identification of Clipped Nodes in Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy // Ann. Surg. Oncol. 2018. Vol. 25, № 10. P. 3030–3036.
  37. Donker M. et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure // Ann. Surg. 2015. Vol. 261, № 2. P. 378–382.
  38. Houssami N. et al. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis // Ann. Surg. Oncol. 2014. Vol. 21, № 3. P. 717–730.
  39. Choi J. et al. Margins in Breast-Conserving Surgery After Neoadjuvant Therapy // Ann. Surg. Oncol. 2018. Vol. 25, № 12. P. 3541–3547.
  40. Budach W. et al. DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases // Strahlenther. Onkol. Organ Dtsch. Rontgengesellschaft Al. 2015. Vol. 191, № 8. P. 623–633.
  41. Meattini I. Accelerated Partial-Breast Irradiation Compared Winh Whole Breast Irradiated for early breast cancer: long term results of the randomized phase III APBI-IMRT Florence Trial J Clin Oncol. 2020 Dec 10;38(35):4175-418
  42. EBCTCG (Early Breast Cancer Trialists' Collaborative Group) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials The Lancet 2014 Vol 383, issue 9935, p 2127-2135, 2014
  43. Божок А.А. и др. Оценка результатов НИР РООМ «Возможности хирургического лечения больных раком молочной железы IV стадии» // Опухоли женской репродуктивной системы. 2016. Т. 4, № 4. P. 17–24
  44. Storto G. et al. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases // Bone. 2006. Vol. 39, № 1. P. 35–41.
  45. Gongling Peng et al. Can a subgroup at high risk for LRR be identified from T1-2 breast cancer with negative lymph nodes after mastectomy? A meta-analysis Biosci Rep. 2019 Sep 30; 39(9): BSR20181853.
  46. Chaichana K.L. et al. Survival and recurrence for patients undergoing surgery of skull base intracranial metastases // J. Neurol. Surg. Part B Skull Base. 2013. Vol. 74, № 4. P. 228–235.
  47. Зикириходжаев А.Д., Ермощенкова А.Х., Исмагилов С.М. Клинические рекомендации РООМ по диагностике и лечению рака молочной железы. 2018.
  48. ICRU Report 50: Prescribing, Recording and Reporting Photon Beam Therapy. Bethesda: International Commission on Radiation Units and Measurements, 1993.
  49. ICRU Report 62: Prescribing, Recording and Reporting Photon Beam Therapy. Bethesda: International Commission on Radiation Units and Measurements, 1999.
  50. ICRU Report 83 // Journal of the ICRU. 2010. Vol. 10, № 1.
  51. Breast Cancer Atlas for Radiation Therapy Planning: Consensus Definition RTOG.
  52. Marks L.B. et al. Use of normal tissue complication probability models in the clinic // Int. J. Radiat. Oncol. Biol. Phys. 2010. Vol. 76, № 3. Suppl. P. S10–19.
  53. Артемова Н.А., Минайло И.И., Страх А.Г. Предлучевая подготовка с использованием объемного планирования: инструкция по применению. Минск, 2009.
  54. Coles C.E. et al. International Guidelines irradiation therapy for breast Cancer during the COVID-19 Pandemic. J Clin Oncol 2020;32:279–81.
  55. Brunt A.M. et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks FAST-Forward 5 year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomized, phase 3 trial. Lancet 2020;395(10237):1613–26.
  56. Caponio R. Waiting time for radiation therapy after breast-conserving surgery in early breast cancer: a retrospective analysis of local relapse and distant metastases in 615 patients Eur J Med Res 2016; 21, 32
  57. Whelan T.J. et al. External Beam accelerated partial breast irradiation versus whole breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomized controlled trial. Lancet 2019;394:2165–72.
  58. Vicini F.A. Long-term primaty resultsof accelerated partial 5-2164 breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomized phase 3, equivalence trial. Lancet 2019;394:215.
  59. National Comprehensive Cancer Network. NCCN practice guidelines for breast cancer (version 4.2021).
  60. Kammerer E. et al. Proton therapy for locally advanced breast cancer: A systematic review of the literature // Cancer Treat. Rev. 2018. Vol. 63. P. 19–27.
  61. Singh P. et al. Neoadjuvant Radiotherapy to Facilitate Immediate Breast Reconstruction: A Systematic Review and Current Clinical Trials // Ann. Surg. Oncol. 2019. Vol. 26, № 10. P. 3312–3320.
  62. Smith B.D.et al. In ASTRO APBI guidelines for early-stage breast cancer International Journal Rad. Oncology Biology Physics 2009 Vol 74,Issue 4, P.987-1001
  63. Robar J.L. et al. Intrapatient study comparing 3D printed bolus versus standard vinyl gel sheet bolus for postmastectomy chest wall radiation therapy // Pract. Radiat. Oncol. 2018. Vol. 8, № 4. P. 221–229
  64. Mayadev J. et al. Practice patterns in the delivery of radiation therapy after mastectomy among the University of California Athena Breast Health Network // Clin. Breast Cancer. 2015. Vol. 15, № 1. P. 43–47
  65. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials // Lancet Lond. Engl. 2011. Vol. 378, № 9804. P. 1707–1716.
  66. Virnig B.A. et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes // J. Natl. Cancer Inst. 2010. Vol. 102, № 3. P. 170–178.
  67. Goodwin A. et al. Post-operative radiotherapy for ductal carcinoma in situ of the breast – a systematic review of the randomised trials // Breast Edinb. Scotl. 2009. Vol. 18, № 3. P. 143–149.
  68. Трофимова О.П. Стратегия лучевой терапии в органосберегающем лечении больных раком молочной железы. Диссертация на соискание ученой степени доктора медицинских наук. Москва, 2015.
  69. Bartelink H. et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial // Lancet Oncol. 2015. Vol. 16, № 1. P. 47–56.
  70. Mithal N.P., Needham P.R., Hoskin P.J. Retreatment with radiotherapy for painful bone metastases // Int. J. Radiat. Oncol. Biol. Phys. 1994. Vol. 29, № 5. P. 1011–1014.
  71. Gerszten P.C. et al. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution // Spine. 2007. Vol. 32, № 2. P. 193–199.
  72. Белозерова М.С., Кочетова Т.Ю., Крылов В.В. Практические рекомендации по радионуклеотидной терапии при метастазах в кости [Electronic resource]. URL: https://docplayer.ru/48355055-Prakticheskie-rekomendacii-po-radionuklidnoy-terapii-pri-metast azah-v-kosti.html.
  73. Abe Е., Aoyama Н. et al. The role of whole brain radiation therapy for the management of brain metastases in the era of stereotactic radiosurgery // Current oncology reports. ‒ Et al. ‒ Vol. 14, № 1. P. 79–84.
  74. Patchell R.A., Tibbs P.A., Regine W.F. et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial // JAMA. 1998. T. 280. № 17. P. 1485–1489.
  75. Tsao M., Xu W., Sahgal A. A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases // Cancer. 2012. Vol. 118. № 9. P. 2486–2493.
  76. Kocher M., Soffietti R., Abacioglu U. et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases // Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011. Vol. 29. № 2. P. 134–141.
  77. Голанов А.В., Бекяшев А.Х., Банов С.М. Клинические рекомендации Минздрава России «Метастатическое поражение головного мозга», 2017.
  78. Bree E.R., Brian G., Roshan P. et al. Hypofractionated radiosurgery for intact or resected brain metastases: defining the optimal dose and fractionation // Radiation oncology (London, England). 2013. Vol. 8. P. 135.
  79. Lippitz Bodo, Lindquist Christer, Paddick Ian. et al. Stereotactic radiosurgery in the treatment of brain metastases // Cancer Treatment Reviews. 2014. Vol. 40, № 1. P. 48–59.
  80. Yamamoto M., Kawabe T., Sato Y. Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2–9 versus 10 or more tumors // Journal of neurosurgery. 2014. Vol. 121. Suppl. P. 16–25.
  81. Regine W.F, Scott C., Murray K., Curran W. Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs accelerated-hyperfractionated radiotherapy // International Journal of Radiation Oncology, Biology, Physics. 2001. Vol. 51, № 40.
  82. Cortazar P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis // Lancet Lond. Engl. 2014. Vol. 384, № 9938. P. 164–172.
  83. DeMichele A. et al. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer // Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2015. Vol. 21, № 13. P. 2911–2915.
  84. Семиглазов В.Ф., Манихас Г.М., Палтуев Р.М. Клинические рекомендации РООМ [Electronic resource] // Российское общество онкомаммологов. URL: http://breastcancersociety.ru/rek/view/227.
  85. Gnant M., Harbeck N., Thomssen C. St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment // Breast Care Basel Switz. 2017. Vol. 12, № 2. P. 102–107.
  86. Sharma P. et al. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts // Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2017. Vol. 23, № 3. P. 649–657.
  87. Levine M. Epirubicin in breast cancer: present and future // Clin. Breast Cancer. 2000. Vol. 1. Suppl 1. P. S62–67.
  88. Galligioni E. et al. High dose epirubicin and cyclophosphamide (EC) vs cyclophosphamide, methotrexate, fluorouracil (CMF) as adjuvant chemotherapy in high risk premenopausal breast cancer patients (PTS). A prospective randomized trial // Eur. J. Cancer. 1998. Vol. 34, № 1001. P. S36.
  89. Bontenbal M. et al. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group // Br. J. Cancer. 1998. Vol. 77, № 12. P. 2257–2263.
  90. Bacrie J. et al. Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution // Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer. 2018. Vol. 26, № 12. P. 4097–4103.
  91. Gianni L. et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort // Lancet Lond. Engl. 2010. Vol. 375, № 9712. P. 377–384.
  92. Gianni L. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial // Lancet Oncol. 2012. Vol. 13, № 1. P. 25–32.
  93. Schneeweiss A. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2013. Vol. 24, № 9. P. 2278–2284. 96. Semiglazov V.F. et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer // Cancer. 2007. Vol. 110, № 2. P. 244–254.
  94. Penault-Llorca F., Radosevic-Robin N. Ki-67 assessment in breast cancer: an update // Pathology (Phila.). 2017. Vol. 49, № 2. P. 166–171.
  95. Rossi D. et al. Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer // Anticancer. Drugs. 2008. Vol. 19, № 7. P. 733–737.
  96. Mamounas E.P. et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27 // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2012. Vol. 30, № 32. P. 3960–3966.
  97. Heys S.D., Sarkar T., Hutcheon A.W. Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival // Breast Cancer Res. Treat. 2005. Vol. 90, № 2. P. 169–185.
  98. Gianni L. et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy // Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2005. Vol. 11, № 24. Pt. 1. P. 8715–8721.
  99. Valero V. et al. Primary chemotherapy in the treatment of breast cancer: the University of Texas M.D. Anderson Cancer Center experience // Clin. Breast Cancer. 2002. Vol. 3. Suppl 2. P. S63–68.
  100. Gonzalez-Angulo A.M. et al. Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer // Clin. Breast Cancer. 2008. Vol. 8, № 6. P. 516–521.
  101. Ohnoa S. et al. Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer // Biomed. Pharmacother. Biomedecine Pharmacother. 2005. Vol. 59. Suppl 2. P. S323–324.
  102. Heller W. et al. Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer // Oncol. Rep. 2007. Vol. 17, № 1. P. 253–259.
  103. Green M.C. et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2005. Vol. 23, № 25. P. 5983–5992.
  104. Mauri D., Pavlidis N., Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97:188–94. DOI: 10.1093/jnci/dji021.
  105. Gianni L., Pienkowski T., Im Y.H. et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, openlabel, phase 2 randomised trial. Lancet Oncol 2016;17:791–800.
  106. Symmans W.F., Wei C., Gould R. et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol 2017;35:1049–60. DOI: 10.1200/JCO.2015.63.1010.
  107. Von Minckwitz G., Huang C.S., Mano M.S. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019;380(7):617–28.
  108. Lluch A., Barrios C.H., Torrecillas L. et al.; GEICAM Spanish Breast Cancer Group; CIBOMA (Iberoamerican Coalition for Research in Breast Oncology); LACOG (Latin American Cooperative Oncology Group). Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol 2020;38(3):203–13. DOI: 10.1200/JCO.19.00904.
  109. Burstein H.J., Curigliano G., Thürlimann B. et al.; Panelists of the St Gallen Consensus Conference. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 2021:S0923-7534(21)02104-9. DOI: 10.1016/j.annonc.2021.06.023.
  110. Masuda N., Lee S.J., Ohtani S. et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017;376:2147–59.
  111. Natori A., Ethier J.L., Amir E. et al. Capecitabine in early breast cancer: a meta-analysis of randomised controlled trials. Eur J Cancer 2017;77:40–7.
  112. Zhang Z.C., Xu Q.N., Lin S.L. et al. Capecitabine in combination with standard (Neo)adjuvant regimens in early breast cancer: survival outcome from a meta-analysis of randomized controlled trials. PLoS One 2016;11:e0164663. DOI: 10.1371/journal.pone.0164663.
  113. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials // Lancet Lond. Engl. 2012. Vol. 379, № 9814. P. 432–444.
  114. Fujii T. et al. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis // JAMA Oncol. 2015. Vol. 1, № 9. P. 1311–1318.
  115. Watanabe T. et al. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study // Cancer. 2017. Vol. 123, № 5. P. 759–768.
  116. Henderson I.C. et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2003. Vol. 21, № 6. P. 976–983.
  117. Sparano J.A. et al. Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer // N. Engl. J. Med. 2008. Vol. 358, № 16. P. 1663–1671.
  118. Cameron D. et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial // Lancet Lond. Engl. 2017. Vol. 389, № 10075. P. 1195–1205.
  119. Hurvitz S.A. et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial // Lancet Oncol. 2018. Vol. 19, № 1. P. 115–126.
  120. Slamon D. et al. Adjuvant trastuzumab in HER2-positive breast cancer // N. Engl. J. Med. 2011. Vol. 365, № 14. P. 1273–1283.
  121. Perez E.A. et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011. Vol. 29, № 25. P. 3366–3373.
  122. Von Minckwitz G. et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer // N. Engl. J. Med. 2017. Vol. 377, № 2. P. 122–131.
  123. Saha P. et al. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017. Vol. 35, № 27. P. 3113–3122.
  124. Criscitiello C. et al. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer // Breast Edinb. Scotl. 2014. Vol. 23, № 1. P. 69–75.
  125. Francis P.A. et al. Adjuvant ovarian suppression in premenopausal breast cancer // N. Engl. J. Med. 2015. Vol. 372, № 5. P. 436–446.
  126. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials // Lancet Lond. Engl. 2011. Vol. 378, № 9793. P. 771–784.
  127. Davies C. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial // Lancet Lond. Engl. 2013. Vol. 381, № 9869. P. 805–816.
  128. Regan M.M. et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8·1 years median follow-up // Lancet Oncol. 2011. Vol. 12, № 12. P. 1101–1108.
  129. Cuzick J. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial // Lancet Oncol. 2010. Vol. 11, № 12. P. 1135–1141.
  130. Derks M.G.M. et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial // Lancet Oncol. 2017. Vol. 18, № 9. P. 1211–1220.
  131. Gnant M. et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial // Lancet Lond. Engl. 2015. Vol. 386, № 9992. P. 433–443.
  132. Albain K.S. Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in a Randomized Trial of Chemotherapy for Postmenopausal, Node-Positive, Estrogen Receptor-Positive Breast Cancer. Lancet Oncol 2010;11(1):55–65. DOI: 10.1016/S1470-2045(09)70314-6.
  133. Yang Z.-J. The prognostic value of node status in different breast cancer subtypes. Oncotarget. 2017;8(3):4563–71. DOI: 10.18632/oncotarget.13943.
  134. Pan H. et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med 2017;377:1836–46. DOI: 10.1056/NEJMoa1701830.
  135. Lænkholm A. PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer. J Clin Oncol 2018;36:735–40.
  136. Johnston S.R.D. et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR1, HER22, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020;38(34):3987–98.
  137. Martin M.M. et al. Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC). American Society of Clinical Oncology. Virtual Online. June 4–8, 2021.
  138. Rastogi P. et al. SABCS 2020; presentation number GS1-01.
  139. O’Shaughnessy J. et al. Poster presented at: PragueONCO 2021.
  140. Rugo H. et al. Safety outcomes from monarchE: phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+ HER2-, node-positive, high risk, early breast cancer. St. Gallen Breast Cancer Conference, 2021.
  141. Колядина И.В. Диссертационная работа на соискание ученой степени кандидата медицинских наук. Локальные рецидивы первично-операбельного рака молочной железы. Москва, 2009.
  142. Уйманов В.А., Нечушкин М.И., Гладилина И.А. Прогностические факторы развития местного рецидива после органосохраняющего лечения ранних стадий рака молочной железы. Состояние проблемы. Опухоли женской репродуктивной системы. 2009, № 1–2. С. 16–20.
  143. Пасько М.А., Захаренко М.В., Троценко И.Д., Кудинова Е.А, Чхиквадзе В.Д., Боженко В.К. Определение риска локорегиональных рецидивов рака молочной железы после органосохраняющего лечения на основе анализа экспрессии генов. Вестник РНЦРР. Москва, 2015.
  144. Поддубная И.В., Комов Д.В., Колядина И.В., Керимов Р.А., Рощин Е.М. Современный взгляд на проблему локальных рецидивов рака молочной железы. СТМ, 2009, № 5. С.70–83.
  145. Уйманов В.А., Нечушкин М.И., Гладилина И.А. Отдаленный прогноз у пациенток с местным рецидивом рака молочной железы после органосохраняющего лечения. Опухоли женской репродуктивной системы. 2009, № 3–4. С. 5–9.
  146. Silviu Cristian Voinea, Angela Sandru , Alexandru Blidaru. Management of Breast Cancer Locoregional Recurrence Chirurgia, 2017, Vol. 112, № 4. P. 429–435.
  147. Coates A.S., Winer E.P., Goldhirsch A. et al. Current Strategies for the Management of Locoregional Breast Cancer Recurrence. Tailoring therapies – improving the management of early breast cancer: St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology. 2015. Vol. 26. P. 1533–1546.
  148. Gradishar W.J. et al. NCCN Clinical Practice Guidelines in Oncology. Breast cancer. Version 2. 2016.
  149. Aurilio G. et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases // Eur. J. Cancer Oxf. Engl. 1990. 2014. Vol. 50, № 2. P. 277–289.
  150. Schrijver W.A.M.E. et al. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis // J. Natl. Cancer Inst. 2018. Vol. 110, № 6. P. 568–580. 154. Ieni A. et al. Letter to the Editor regarding the paper by Aurilio et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases // Eur. J. Cancer Oxf. Engl. 1990. 014. Vol. 50, № 5. P. 1035–1037.
  151. Переводчикова Н.И. Руководство по химиотерапии опухолевых заболеваний. 2018. 688 стр.
  152. Cardoso F. et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) // Breast Edinb. Scotl. 2014. Vol. 23, № 5. P. 489–502.
  153. Nabholtz J.M. et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2000. Vol. 18, № 22. P. 3758–3767.
  154. Mouridsen H. et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2003. Vol. 21, № 11. P. 2101–2109.
  155. Patterson-Lomba O. et al. Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer // Breast J. 2019. 160. Milla-Santos A. et al. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer // Breast Cancer Res. Treat. 2001. Vol. 65, № 2. P. 119–124.
  156. Ellis A.J. et al. Selective estrogen receptor modulators in clinical practice: a safety over view // Expert Opin. Drug Saf. 2015. Vol. 14, № 6. P. 921–934.
  157. Metindir J., Aslan S., Bilir G. Ovarian cyst formation in patients using tamoxifen for breast cancer // Jpn. J. Clin. Oncol. 2005. Vol. 35, № 10. P. 607–611.
  158. Henry N.L. et al. Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation // Clin. Breast Cancer. 2017. Vol. 17, № 5. P. 350–355.e.4.
  159. Anderson R.A. et al. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer // Eur. J. Cancer Oxf. Engl. 1990. 2017. Vol. 87. P. 58–64.
  160. Mouridsen H. et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2001. Vol. 19, № 10. P. 2596–2606.
  161. Finn R.S. et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 // Breast Cancer Res. BCR. 2016. Vol. 18, № 1. P. 67.
  162. O’Shaughnessy J. et al. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial // Breast Cancer Res. Treat. 2018. Vol. 168, № 1. P. 127–134.
  163. Hortobagyi G.N. et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2018. Vol. 29, № 7. P. 1541–1547.
  164. Paridaens R.J. et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008. Vol. 26, № 30. P. 4883–4890.
  165. Baselga J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer // N. Engl. J. Med. 2012. Vol. 366, № 6. P. 520–529.
  166. Di Leo A. et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010. Vol. 28, № 30. P. 4594–4600.
  167. Maura N. Dickler 1, Sara M. Tolaney 2, Hope S. Rugo et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017;23(17):5218–5224. DOI: 10.1158/1078-0432.CCR-17-0754.
  168. André F., Ciruelos E., Rubovszky G. et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. SOLAR-1 Study Group. N Engl J Med. 2019;380(20):1929–1940. DOI: 10.1056/NEJMoa1813904.
  169. Robertson J.F.R. et al. Activity of fulvestrant in HER2-overexpressing advanced breast cancer // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2010. Vol. 21, № 6. P. 1246–1253.
  170. Finn R.S. et al. Palbociclib and Letrozole in Advanced Breast Cancer // N. Engl. J. Med. 2016. Vol. 375, № 20. P. 1925–1936.
  171. Slamon D.J. et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2018. Vol. 36, № 24. P. 2465–2472.
  172. Cardoso F. et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2017. Vol. 28, № 1. P. 16–33.
  173. Kramer J.A. et al. Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist // Eur. J. Cancer Oxf. Engl. 1990. 2000. Vol. 36, № 12. P. 1488–1497.
  174. O’Brien M.E.R. et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2004. Vol. 15, № 3. P. 440–449.
  175. Hainsworth J.D. et al. Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial // Cancer Invest. 2006. Vol. 24, № 5. P. 469–473.
  176. Nelli F. et al. Epirubicin and docetaxel as first-line treatment for hormonal receptor positive metastatic breast cancer: the predictive value of luminal subtype: a retrospective cohort analysis // J. Chemother. Florence Italy. 2013. Vol. 25, № 2. P. 112–118.
  177. Nabholtz J.M. et al. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer // Oncol. Williston Park N. 1997. Vol. 11, № 8. Suppl 8. P. 25–30. 183. Perez E.A. Paclitaxel in Breast Cancer // The Oncologist. 1998. Vol. 3, № 6. P. 373–389. 184. Lück H.J. et al. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer // Oncol. Williston Park N. 1997. Vol. 11, № 4. Suppl 3. P. 34–37.
  178. Perez E.A. et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2001. Vol. 19, № 22. P. 4216–4223. 186. Liu Y. et al. Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials // Oncotarget. 2017. Vol. 8, № 42. P. 72950–72958.
  179. Aapro M., Finek J. Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results // Cancer Treat. Rev. 2012. Vol. 38, № 2. P. 120–126.
  180. Lüftner D. et al. Gemcitabine for palliative treatment in metastatic breast cancer // J. Cancer Res. Clin. Oncol. 1998. Vol. 124, № 10. P. 527–531.
  181. Perez E.A. et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007. Vol. 25, № 23. P. 3407–3414.
  182. Blum J.L. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer // The Oncologist. 2001. Vol. 6, № 1. P. 56–64.
  183. Talbot D.C. et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines // Br. J. Cancer. 2002. Vol. 86, № 9. P. 1367–1372.
  184. Cortes J. et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study // Lancet Lond. Engl. 2011. Vol. 377, № 9769. P. 914–923.
  185. Kaufman P.A. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2015. Vol. 33, № 6. P. 594–601.
  186. Cinieri S. et al. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer // Clin. Breast Cancer. 2017. Vol. 17, № 2. P. 91–99.e1.
  187. Li J. et al. Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study // Medicine (Baltimore). 2015. Vol. 94, № 41. P. e1340.
  188. Thomas E.S. et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007. Vol. 25, № 33. P. 5210–5217.
  189. Wagner L., Wang M., Miller K. et al. Health-related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: results from the Eastern Cooperative Oncology Group (ECOG) study E2100. Breast Cancer Res Treat 2006;100(Suppl. 1):S239.
  190. Marty M. et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2005. Vol. 23, № 19. P. 4265–4274.
  191. Slamon D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 // N. Engl. J. Med. 2001. Vol. 344, № 11. P. 783–792.
  192. Kaufman B. et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009. Vol. 27, № 33. P. 5529–5537.
  193. Swain S.M. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study // Lancet Oncol. 2013. Vol. 14, № 6. P. 461–471.
  194. Stravodimou A., Zaman K., Voutsadakis I.A. Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series // ISRN Oncol. 2014. Vol. 2014. P. 289836.
  195. Bergen E. et al. Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer // Breast Care. 2014. Vol. 9, № 5. P. 344–348.
  196. Farhat F., Kattan J.G., Ghosn M. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer // Cancer Chemother. Pharmacol. 2016. Vol. 77, № 5. P. 1069–1077.
  197. Фармакотерапия опухолей. Посвящается памяти Михаила Лазаревича Гершановича // А.Н. Стуков и коллектив авторов / Под ред. А.Н. Стукова, М.А. Бланка, Т.Ю. Семиглазовой, А.М. Беляева. СПб: Издательство АНО «Вопросы онкологии», 2017, 512 с.
  198. Von Minckwitz G. et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer // Eur. J. Cancer Oxf. Engl. 1990. 2011. Vol. 47, № 15. P. 2273–2281.
  199. Blackwell K.L. et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010. Vol. 28, № 7. P. 1124–1130.
  200. Verma S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer // N. Engl. J. Med. 2012. Vol. 367, № 19. P. 1783–1791.
  201. Geyer C.E. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer // N. Engl. J. Med. 2006. Vol. 355, № 26. P. 2733–2743.
  202. Johnston S. et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009. Vol. 27, № 33. P. 5538–5546.
  203. Stockler M.R. et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011. Vol. 29, № 34. P. 4498–4504.
  204. Fedele P. et al. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer // Eur. J. Cancer Oxf. Engl. 1990. 2012. Vol. 48, № 1. P. 24–29.
  205. Martín M. et al. Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis // The Oncologist. 2015. Vol. 20, № 2. P. 111–112.
  206. Taguchi T, Nakayama T, Masuda N, Yoshidome K, Akagi K, Nishida Y, Yoshikawa Y, Ogino N, Abe C, Sakamoto J, Noguchi S; Kinki Breast Cancer Study Group. Study of low-dose capecitabine monotherapy for metastatic breast cancer. Chemotherapy. 2010;56(2):166-70.
  207. Briasoulis E. et al. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer // Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2009. Vol. 15, № 20. P. 6454–6461.
  208. Addeo R. et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer // Clin. Breast Cancer. 2010. Vol. 10, № 4. P. 301–306.
  209. Montagna E. et al. 1876 A phase II study of metronomic oral chemotherapy for metastatic breast cancer patients: Safety and efficacy results of vinorelbine, cyclophosphamide plus capecitabine (VEX) combination // Eur. J. Cancer. 2015. Vol. 51. P. S291–S292.
  210. Cazzaniga M.E. et al. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study // Breast Edinb. Scotl. 2019. Vol. 8. P. 7–16.
  211. Yoshimoto M. et al. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer // Cancer Chemother. Pharmacol. 2012. Vol. 70, № 2. P. 331–338.
  212. Wang H. et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer // PloS One. 2012. Vol. 7, № 4. P. e34210.
  213. Addeo R. et al. Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases // Cancer Chemother. Pharmacol. 2012. Vol. 70, № 4. P. 603–609.
  214. Colleoni M. et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2002. Vol. 13, № 1. P. 73–80.
  215. Colleoni M. et al. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00 // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2016. Vol. 34, № 28. P. 3400–3408.
  216. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s–9s.
  217. von Moos R., Costa L., Gonzalez-Suarez E. et al. Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody. Cancer Treat Rev. 2019;76:57–67. 226. Galasko C.S. The value of scintigraphy in malignant disease. Cancer Treat Rev 1975;2:225–72.
  218. Лишманов Ю.Б., Чернов В.И. Радионуклидная диагностика для практических врачей. Томск, 2004. С. 280–285.
  219. Vogel C.L., Schoenfelder J., Shemano I. et al. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 1995; 13: 1123–1128. 229. Woolf D.K., Padhani A.R., Makris A. Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care? Ann Oncol 2015;26:1048–57.
  220. Citrin D.L., Bessent R.G., Greig W.R. A comparison of the sensitivity and accuracy of the 99m Tc-phosphate bone scan and skeletal radiograph in the diagnosis of bone metastases. Clin Radiol. 1977;28:107–17.
  221. Yang H.L., Liu T., Wang X.M. et al. Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 2011;21(12):2604–17. DOI: 10.1007/s00330-011-2221-4.
  222. Eisenhauera E.A., Therasseb P., Bogaertsc J., et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–47.
  223. Hamaoka T., Costelloe C.M., Madewell J.E. et al. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer 2010;102:651–7.
  224. Costelloe C.M., Chuang H.H., Madewell J.E., Ueno N.T. Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. J Cancer 2010;1:80–92.
  225. Hamaoka T., Madewell J.E., Podoloff D.A. et al. Bone imaging in metastatic breast cancer. J Clin Oncol 2004;22:2942-53.
  226. Schmid P. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer // N. Engl. J. Med. 2018. Vol. 379, № 22. P. 2108–2121.
  227. Coates A.S. PG 0.1 Evolution of the St.Gallen Consensus process for the optimal treatment of women with breast cancer // The Breast. 2015. Vol. 24. P. S1.
  228. Nilsson MP, Hartman L, Kristoffersson U, et al: High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast Cancer Res Treat 147:571-578, 2014.
  229. Pierce LJ, Phillips KA, Griffith KA, et al: Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: Comparison of breast conservation and mastectomy. Breast Cancer Res Treat 121:389-398, 2010.
  230. van den Broek AJ, Schmidt MK, van’t Veer LJ, et al: Prognostic impact of breast-conserving therapy versus mastectomy of BRCA1/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients. Ann Surg 270:364-372, 2019.
  231. Tang NM, Boughey JC, Pierce LJ etal: Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol 38(18): 2080-21016, 2020.
  232. Manning AT, Wood C, Eaton A, et al: Nipple-sparing mastectomy in patients with BRCA1/2 mutations and variants of uncertain significance. Br J Surg 102:1354-1359, 2015.
  233. Yao K, Liederbach E, Tang R, et al: Nipple-sparing mastectomy in BRCA1/2 mutation carriers: An interim analysis and review of the literature. Ann Surg Oncol 22:370-376, 2015 Ann Surg Oncol 21:S788, 2014 (suppl 4).
  234. Cao W, Xie Y, He Y, et al: Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China. Breast Cancer Res Treat 175:749-754, 2019.
  235. Park H, Choi DH, Noh JM, et al: Acute skin toxicity in Korean breast cancer patients carrying BRCA mutations. Int J Radiat Biol 90:90-94, 2014.
  236. Pierce LJ, Strawderman M, Narod SA, et al: Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18:3360-3369, 2000.
  237. Shanley S, McReynolds K, Ardern-Jones A, et al: Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res 12:7025-7032, 2006.
  238. Heymann S, Delaloge S, Rahal A, et al: Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 5:104, 2010.
  239. Limacher JM, Frebourg T, Natarajan-Ame S, et al: Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 96:238-242, 2001.
  240. Salmon A, Amikam D, Sodha N, et al: Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline ‘de-novo’ TP53 mutation. Clin Oncol (R Coll Radiol) 19:490-493, 2007.
  241. Soenderstrup IMH, Laenkholm AV, Jensen MB, et al: Clinical andmolecular characterization of BRCA-associated breast cancer: Results from the DBCG. Acta Oncol 57:95-101, 2018.
  242. van Sprundel TC, Schmidt MK, Rookus MA, et al: Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93:287-292, 2005.
  243. Carbine NE, Lostumbo L, Wallace J, et al: Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev 4:CD002748, 2018.
  244. Jakub JW, Peled AW, Gray RJ, et al: Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: A multi-institutional study. JAMA Surg 153:123-129, 2018.
  245. Tutt A, Tovey H, Cheang MCU, et al: Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT trial. Nat Med 24:628-637, 2018. 256. Hahnen E, Lederer B, Hauke J, et al: Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: Secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol 3:1378-1385, 2017.
  246. Loibl S, O’Shaughnessy J, Untch M, et al: Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): A randomised, phase 3 trial. Lancet Oncol 19:497-509, 2018.
  247. Robson M, Im SA, Senkus E, et al: Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523-533, 2017.
  248. Litton JK, Rugo HS, Ettl J, et al: Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379:753-763, 2018.
  249. Hurvitz SA, Gonçalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. Oncologist. 2019 Nov 25. pii: theoncologist.2019-0493. doi: 10.1634/theoncologist.2019-049.
  250. Bremer M, Klöpper K, Yamini P, et al: Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: No observation of increased radiation-induced acute or late effects. Radiother Oncol 69:155-160, 2003.
  251. Broeks A, Braaf LM, Huseinovic A, et al: Identification of women with an increased risk of developing radiation-induced breast cancer: A case only study. Breast Cancer Res 9:R26, 2007.
  252. Iannuzzi CM, Atencio DP, Green S, et al: ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys 52:606-613, 2002.
  253. Meyer A, John E, Dörk T, et al: Breast cancer in female carriers of ATM gene alterations: Outcome of adjuvant radiotherapy. Radiother Oncol 72:319-323, 2004.
  254. Su Y, Swift M: Outcomes of adjuvant radiation therapy for breast cancer in women with ataxia-telangiectasia mutations. JAMA 286:2233-2234, 2001.
  255. Broeks A, de Witte L, Nooijen A, et al: Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat 83:91-93, 2004.
  256. Cybulski C, Klu´zniak W, Huzarski T, et al: Clinical outcomes in women with breast cancer and a PALB2 mutation: A prospective cohort analysis. Lancet Oncol 16:638-644, 2015. 268. Fletcher O, Johnson N, Dos Santos Silva I, et al: Family history, genetic testing, and clinical risk prediction: Pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. Cancer Epidemiol Biomarkers Prev 18:230-234, 2009.
  257. Kriege M, Hollestelle A, Jager A, et al: Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: Impact of adjuvant chemotherapy. Br J Cancer 111:1004-1013, 2014.
  258. Weischer M, Nordestgaard BG, Pharoah P, et al: CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer specific death, and increased risk of a second breast cancer. J Clin Oncol 30:4308-4316, 2012.
  259. Contrast Manual [Electronic resource]. URL: https://www.acr.org/Clinical-Resources/Contrast-Manual.
  260. Amant F. et al. Breast cancer in pregnancy // Lancet Lond. Engl. 2012. Vol. 379, № 9815. P. 570–579.
  261. Loibl S. et al. Breast carcinoma during pregnancy. International recommendations from an expert meeting // Cancer. 2006. Vol. 106, № 2. P. 237–246.
  262. Gentilini O. et al. Sentinel lymph node biopsy in pregnant patients with breast cancer // Eur. J. Nucl. Med. Mol. Imaging. 2010. Vol. 37, № 1. P. 78–83.
  263. Ellner S.J. et al. Dose-dependent biodistribution of [(99m)Tc] DTPA-mannosyl-dextran for breast cancer sentinel lymph node mapping // Nucl. Med. Biol. 2003. Vol. 30, № 8. P. 805–810.
  264. Khera S.Y. et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping // Breast J. 2008. Vol. 14, № 3. P. 250–254.
  265. Peccatori F.A. et al. Weekly epirubicin in the treatment of gestational breast cancer (GBC) // Breast Cancer Res. Treat. 2009. Vol. 115, № 3. P. 591–594.
  266. Azim H.A. et al. Anthracyclines for gestational breast cancer: course and outcome of pregnancy // Ann. Oncol. 2008. Vol. 19, № 8. P. 1511–1512.
  267. Zagouri F. et al. Taxanes for breast cancer during pregnancy: a systematic review // Clin. Breast Cancer. 2013. Vol. 13, № 1. P. 16–23.
  268. Cullins S.L., Pridjian G., Sutherland C.M. Goldenhar’s syndrome associated with tamoxifen given to the mother during gestation // JAMA. 1994. Vol. 271, № 24. P. 1905–1906. 281. Isaacs R.J., Hunter W., Clark K. Tamoxifen as systemic treatment of advanced breast cancer during pregnancy--case report and literature review // Gynecol. Oncol. 2001. Vol. 80, № 3. P. 405–408.
  269. Tewari K. et al. Ambiguous genitalia in infant exposed to tamoxifen in utero // The Lancet. 1997. Vol. 350, № 9072. P. 183.
  270. Gottschalk I. et al. Fetal Renal Insufficiency Following Trastuzumab Treatment for Breast Cancer in Pregnancy: Case Report und Review of the Current Literature // Breast Care Basel Switz. 2011. Vol. 6, № 6. P. 475–478.
  271. Sekar R., Stone P.R. Trastuzumab use for metastatic breast cancer in pregnancy // Obstet. Gynecol. 2007. Vol. 110, № 2. Pt. 2. P. 507–510.
  272. Watson W.J. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios // Obstet. Gynecol. 2005. Vol. 105, № 3. P. 642–643.
  273. Keyser E.A. et al. Pregnancy-associated breast cancer // Rev. Obstet. Gynecol. 2012. Vol. 5, № 2. P. 94–99.
  274. Sanson B.J. et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review // Thromb. Haemost. 1999. Vol. 81, № 5. P. 668–672.
  275. Rugo H.S., Finn R.S., Diéras V. et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-egative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019 ;174(3):719–729. DOI: 10.1007/s10549-018-05125-4.
  276. Tripathy D., Im S.A., Colleoni M. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–915. DOI: 10.1016/S1470–2045(18)30292–4.
  277. Im S.A., Lu Y.S., Bardia A., Harbeck et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019;381(4):307–316. DOI: 0.1056/NEJMoa1903765.
  278. Tanguy M.L., Cabel L., Berger F. et al. Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer. NPJ Breast Cancer. 2018;4:14. DOI: 10.1038/s41523-018-0068-4.
  279. First-Line Abemaciclib Effective in ER+ Breast Cancer. Cancer Discov. 2017;7(11):OF6.
  280. Giuliani J., Bonetti A. The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer. J Oncol Pharm Pract. 2020;26(6):1486–1491.
  281. Cristofanilli M., Turner N.C., Bondarenko I. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439. DOI: 10.1016/S1470-2045(15)00613-0. \
  282. George W. Sledge Jr 1, Masakazu Toi 1, Patrick Neven et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875–2884. DOI: 10.1200/JCO.2017.73.7585.
  283. Imyanitov EN. Breast cancer therapy for BRCA1 carriers: moving towards platinum standard? Hered Cancer Clin Pract. 2009 Apr 20;7(1):8.
  284. Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-1535.
  285. Шмонин А.А., Мальцева М.Н., Мельникова Е.В., Иванова Г.Е. Базовые принципы медицинской реабилитации, реабилитационный диагноз в категориях МКФ и реабилитационный план. Вестник восстановительной медицины 2017;2:16–22.
  286. Семиглазова Т.Ю., Клюге В.А., Каспаров Б.С. и др. Международная модель реабилитации онкологических больных. Медицинский Совет 2018;10:108–16.
  287. De Groef A., Van Kampen M., Dieltjens E. et al. Effectiveness of Postoperative Physical Therapy for Upper Limb Impairments Following Breast Cancer Treatment: A Systematic Review. Archives of physical medicine and rehabilitation 2015.
  288. Odynets T., Briskin Y., Todorova V. Effects of Different Exercise Interventions on Quality of Life in Breast Cancer Patients: A Randomized Controlled Trial. Integr Cancer Ther 2019;18:1534735419880598. DOI: 10.1177/1534735419880598.
  289. Pettee Gabriel K., Sternfeld B., Colvin A.B. et al. The impact of breast cancer on physical activity from midlife to early older adulthood and predictors of change post-diagnosis. J Cancer Surviv 2020;14(4):545–55. DOI: 10.1007/s11764-020-00879-7.
  290. Bourke L., Homer K.E., Thaha M.A. et al. Interventions for promoting habitual exercise in people living with and beyond cancer (Review). Cochrane Database of Systematic Reviews. 2013;9:Art.CD010192. DOI: 10.1002/14651858.CD010192.pub2.
  291. Campbell K.L., Winters-Stone K.M., Wiskemann J. et al. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc 2019;51(11):2375–90. DOI: 10.1249/MSS.0000000000002116.
  292. Van Dijck S., Nelissen P., Verbelen H. et al. The effects of physical self-management on quality of life in breast cancer patient: A systematic review. The Breast 2016;28:20–8.
  293. Lytvyn L., Zeraatkar D., Anbari A.B. et al. Conservative Intervention Strategies for Adult Cancer-Related Lymphedema: A Systematic Review and Network Meta-Analysis. Oncol Nurs Forum 2020;47(5):E171–89. DOI: 10.1188/20.ONF.E171-E189.
  294. Rasmussen G.H.F., Kristiansen M., Arroyo-Morales M. et al. Absolute and relative reliability of pain sensitivity and functional outcomes of the affected shoulder among women with pain after breast cancer treatment. PLoS One 2020;15(6):e0234118. DOI: 10.1371/journal.pone.0234118.
  295. Cantarero-Villanueva I., Fernández-Lao C., Fernández-de-las-Peñas C. et al. Effectiveness of Water Physical Therapy on Pain, Pressure Pain Sensitivity, and Myofascial Trigger Points in Breast Cancer Survivors: A Randomized, Controlled Clinical Trial. Pain Medicine 2012;26(1):67–72.
  296. Mourao e Lima M.T.B.R., Mourao e Lima J.G., Carvalho de Andrade M.F., Bergmann A. Low-level laser therapy in secondary lymphedema after breast cancer: systematic review. Lasers Med Sci 2012;18(4):884–90.
  297. Carati C.J., Anderson S.N., Gannon B.J., Piller N.B. Treatment of Postmastectomy Lymphedema with Low-Level Laser Therapy. Cancer 2003;98:1114–22.
  298. Robb K.A., Newham D.J., Williams J.E. Transcutaneous Electrical Nerve Stimulation vs. Transcutaneous Spinal Electroanalgesia for Chronic Pain Associated with Breast Cancer Treatments. Journal of Pain and Symptom Management 2007;4(33):410–9.
  299. Chandwani K.D., Perkins G., Nagendra H.R. et al. Randomized, controlled trial of Yoga in women with breast cancer undergoing radiotherapy. Journal of Clinical Oncology 2014;32(10):1058–66.
  300. Belmonte R., Tejero M., Ferrer M. et al. Efficacy of low-frequency low-intensity electrotherapy in the treatment of breast cancer-related lymphoedema: a cross-over randomized trial. Clinical Rehabilitation 2011;26(7):607–18.
  301. Dos Santos S., Hill N., Morgan A. et al. Acupuncture for Treating Common Side Effects Associated with Breast Cancer Treatment: A Systematic Review. Medical Acupuncture 2010;22(2):233–9.
  302. Leal N.F.B.S., Carrara H.H.A., Vieira K.F., Ferreira C.H.J. Physiotherapy treatments for breast cancer-related lymphedema: A literature review. Rev. Latino-am. Enfermagem 2009;17(5):730–7.
  303. Golant M., Altman T., Martin C. Managing cancer side effects to improve quality of life: a cancer psychoeducation program. Cancer Nurs 2003;26(1):37–44.
  304. Kligman L., Wong R.K., Johnston M., Laetsch N.S. The treatment of lymphedema related to breast cancer: a systematic review and evidence summary. Support Care Cancer 2004;12:421–31.
  305. Tatrow K., Montgomery G.H. Cognitive behavioral therapy techniques for distress and pain in breast cancer patients: a meta‐analysis. J Behav Med 2006;29:17–27.
  306. Онкопсихология для врачей-онкологов и медицинских психологов. Руководство. 2-е изд., доп. // А.М. Беляев и коллектив авторов / Ред. А.М. Беляев, В.А. Чулкова, Т.Ю. Семиглазова, М.В. Рогачев. СПб: Изд-во АНО «Вопросы онкологии», 2018. 436 с.
  307. Coleman E.A., Tulman L., Samarel N. et al. The effect of telephone social support and education on adaptation to breast cancer during the year following diagnosis. Oncol Nurs Forum Online 2005;32(4):822–9.
  308. Meneses K.D., McNees P., Loerzel V.W. et al. Transition from treatment to survivorship: effects of a psychoeducational intervention on quality of life in breast cancer survivors. Oncol Nurs Forum Online 2007;34(5):1007–16.
  309. Sandgren A.K., McCaul K.D. Long‐term telephone therapy outcomes for breast cancer patients. Psycho‐Oncology 2007;16(1):38–47.
  310. Yates P., Aranda S., Hargraves M. et al. Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant chemotherapy for early‐stage breast cancer. J Clin Oncol 2005;23(25):6027–36.
  311. Antoni M.H., Lechner S.C., Kazi A. et al. How stress management improves quality of life after treatment for breast cancer. J Consult Clin Psychol 2006;74(6):1143–52.
  312. Cohen M., Fried G. Comparing relaxation training and cognitive‐behavioral group therapy for women with breast cancer. Res Soc Work Pract 2007;17(3):313–23.
  313. Kissane D.W., Bloch S., Smith G.C. et al. Cognitive‐existential group psychotherapy for women with primary breast cancer: a randomised controlled trial. Psycho‐Oncology 2003;12(6):532–46.
  314. Fukui S., Kugaya A., Okamura H. et al. A psychosocial group intervention for Japanese women with primary breast carcinoma. Cancer 2000;89(5):1026–36.
  315. Dirksen S.R., Epstein D.R. Efficacy of an insomnia intervention on fatigue, mood and quality of life in breast cancer survivors. J Adv Nurs 2008;61(6):664–75.
  316. Lahmann P.H., Friedenreich C., Schuit A.J. et al. Physical activity and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2007;16(1):36-42.
  317. Chlebowski R.T., Luo J., Anderson G.L. et al. Weight change in postmenopausal women and breast cancer risk in the women’s health initiative observational study. SABCS 2017 Abstr. GS5-07.
  318. Li L., Zhong Y., Zhang H. et al. Association between oral contraceptive use as a risk factor and triple-negative breast cancer: a systematic review and meta-analysis. Mol Clin Oncol 2017;7(1):76–80. DOI: 10.3892/mco.2017.1259.
  319. Wang K., Li F., Chen L., et al. Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies. Oncotarget 2017;8(46):81109-24.
  320. Cuzick J., Sestak I., Bonanni B. et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta‑analysis of individual participant data. Lancet 2013;381(9880):1827–34.
  321. Fisher B., Costantino J.P., Wickerham D.L. et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97(22):1652-62.
  322. Goss P.E., Ingle J.N., Ales-Martin L.J. et al. Exemestane for breast cancer prevention in postmenopausal women. N Engl J Med 2011;364(25):2381–91.
  323. Cuzick J., Sestak I., Forbes J.F. et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014;383(9922):1041–8.
  324. Hartmann L.C., Schaid D.J., Woodfs J.E. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999, 340(2):77–84.
  325. Доброкачественная дисплазия молочной железы. Клинические рекомендации. Министерство здравоохранения Российской Федерации. 2020. 56 с.
  326. Van Verschuer V.M.T., Maijers M.C., van Deurzen C.H.M., Koppert L.B. Oncological safety of prophylactic breast surgery: skin-sparing and nipple-sparing versus total mastectomy. Gland Surg 2015;4(6):467–75.
  327. McDonnell S.K., Schaid D.J., Myers J.L. et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001;19(19):3938–43.
  328. Boughey J.C., Hoskin T.L., Degnim A.C. et al. Contralateral Prophylactic Mastectomy is Associated with a Survival Advantage in High-Risk Women with a Personal History of Breast Cancer. Ann Surg Oncol 2010;17(10):2702–9.
  329. Портной С.М., Любченко Л.Н., Блохин С.Н. и др. Профилактика BRCA-ассоциированных рака молочной железы и рака яичников. Обзор литературы и собственные данные. Онкогинекология 2012;(1):68–72.
  330. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность) / Под ред. А.Д. Каприна, В.В. Старинского, Шахзадовой А.О. − М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, − 2020. − илл. − 252 с.
  331. Johnson L.N., Dillon K.E., Sammel M.D. et al. Response to ovarian stimulation in patients facing gonadotoxic therapy. Reprod Biomed Online 2013;26:337–344.
  332. Lambertini M., Moore H.C.F., Leonard R.C.F. et al. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. J Clin Oncol 2018;36:1981–90.
  333. The ESHRE Guideline Group on Ovarian Stimulation; Bosch E., Broer S., Griesinger G. et al. ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum Reprod Open 2020: and www.eshre.eu/guidelines.
  334. Azim H.A. Jr, Kroman N., Paesmans M. et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol 2013;31(1):73–9.
  335. Bedoschi G., Navarro P.A., Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol 2016;12(20):2333–44.
  336. Codacci-Pisanelli G., Del Pup L., Del Grande M. et al. Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients. Crit Rev Oncol Hematol 2017;113:90–6. DOI: 10.1016/j.critrevonc.2017.03.009.
  337. Morgan S., Anderson R.A., Gourley C. et al. How do chemotherapeutic agents damage the ovary? Hum Reprod Update 2012;18(5):525–35.
  338. Marder W., McCune W.J., Wang L. et al. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol 2012;28:624–7.
  339. Shapira M., Raanani H., Feldman B. et al. BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles. Fertil Steril 2015;104:1162–7.
  340. Das M., Shehata F., Moria A. et al. Ovarian reserve, response to gonadotropins, and oocyte maturity in women with malignancy. Fertil Steril 2011;96:122–5.
  341. Alvarez R.M., Ramanathan P. Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response. Hum Reprod 2018;33:2051–9.
  342. Lekovich J., Lobel A.L.S., Stewart J.D. et al. Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies. J Assist Reprod Genet 2016;33(5):657–62.
  343. Edib Z, Jayasinghe Y, Hickey M, Stafford L, Anderson RA, Su HI, Stern K, Saunders C, Anazodo A, Macheras-Magias M, Chang S, Pang P, Agresta F, Chin-Lenn L, Cui W, Pratt S, Gorelik A, Peate M. Exploring the facilitators and barriers to using an online infertility risk prediction tool (FoRECAsT) for young women with breast cancer: a qualitative study protocol. BMJ Open. 2020 Feb 10;10(2):e033669.
  344. Silvestris E, Dellino M, Cafforio P, Paradiso AV, Cormio G, D'Oronzo S. Breast cancer: an update on treatment-related infertility. J Cancer Res Clin Oncol. 2020 Mar;146(3):647-657. 358. Boots C.E., Meister M., Cooper A.R. et al. Ovarian stimulation in the luteal phase: systematic review and meta-analysis. J Assist Reprod Genet 2016;33:971–80.
  345. Rodgers R.J., Reid G.D., Koch J. et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod 2017;32:1033–45.
  346. Cavagna F., Pontes A., Cavagna M. et al. Specific protocols of controlled ovarian stimulation for oocyte cryopreservation in breast cancer patients. Curr Oncol 2018;25:e527–32.
  347. Marklund A. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer – a prospective nationwide Swedish multicenter study. Human reproduction 2020; article in press. 362. Checa Vizcaino M.A., Corchado A.R., Cuadri M.E. et al. The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women. Reprod Biomed Online 2012;24:606–10.
  348. Revelli A., Porcu E., Levi Setti P.E. et al. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol 2013;29:993–6.
  349. Oktay K., Buyuk E., Libertella N. et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005;23:4347–53.
  350. Pereira N., Hancock K., Cordeiro C.N. et al. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytesdagger. Gynecol Endocrinol 2016;32:823–6.
  351. Muteshi C., Child T., Ohuma E., Fatum M. Ovarian response and follow-up outcomes in women diagnosed with cancer having fertility preservation: Comparison of random start and early follicular phase stimulation – cohort study. Eur J Obstet Gynecol Reprod Biol 2018;230:10–4.
  352. Reddy J., Turan V., Bedoschi G. et al. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience. J Assist Reprod Genet 2014;31:927–32.
  353. Garcia-Velasco J.A., Domingo J., Cobo A. et al. Five years’ experience using oocyte vitrification to preserve fertility for medical and nonmedical indications. Fertil Steril 2013;99:1994–9.
  354. Cobo A., Garcia-Velasco J.A., Domingo J. et al. Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients? Fertil Steril 2013;99:1485–95.
  355. Druckenmiller S., Goldman K.N., Labella P.A. et al. Successful Oocyte Cryopreservation in Reproductive-Aged Cancer Survivors. Obstet Gynecol 2016;127:474–80.
  356. Leonard R.C.F., Adamson D.J.A., Bertelli G. et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol 2017;28:1811–6.
  357. Regan M.M., Walley B.A., Francis P.A. et al. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 2017;28:2225–32.
  358. Senra J.C., Roque M., Talim M.C.T. et al. Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2018;51:77–86.
  359. Sinha N., Letourneau J.M., Wald K. et al. Antral follicle count recovery in women with menses after treatment with and without gonadotropin-releasing hormone agonist use during chemotherapy for breast cancer. J Assist Reprod Genet 2018;35:1861–8.
  360. Moore H.C.F., Unger J.M., Phillips K.A. et al. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. J Natl Cancer Inst 2019;111:210–3. 376. Liberman L., Giess C.S., Dershaw D.D. et al. Imaging of pregnancy-associated breast cancer. Radiology 1994;191:245–8.
  361. Robbins J., Jeffries D., Roubidoux M. et al. Accuracy of diagnostic mammography and breast ultrasound during pregnancy and lactation. Am. J. Roentgenol. 2011;196:716–22.
  362. American College of Radiology. ACR manual on contrast media, 2015. Available at: https://www.acr.org//media/ACR/Documents/PDF/QualitySafety/Resources/Contrast-manual/20 16_Contrast_Media.pdf?la=en. Accessed January 10, 2017.
  363. Oyama T., Koibuchi Y., McKee G. Core needle biopsy (CNB) as a diagnostic method for breast lesions: comparison with fine needle aspiration cytology (FNA). Breast Cancer 2004;11(4):339–42.
  364. Amant F., Deckers S., Van Calsteren K. et al. Breast cancer in pregnancy: Recommendations of an international consensus meeting. Eur. J. Cancer 2010;46:3158–68.
  365. Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003;18: 90-95.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*